Cydan, LLC, a Cambridge, Mass.-based orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, has just launched with $16m in financing.
The round was led by New Enterprise Associates (NEA) and Pfizer Venture Investments, with participation from Alexandria Real Estate Equities, Inc.
The accelerator will focus on identifying promising assets across all therapeutic areas in rare diseases, with a focus on diseases and disorders with a characterized genetic etiology, with understood biology and proof-of-concept data in in vivo models from academia, industry and other sources.
Data generated during a de-risking process comprised of outsourced pharmacology, toxicology and other studies will enable it to form companies and strategic partnerships.
The accelerator was founded by
– Cristina Csimma, Pharm.D., Chief Executive Officer.
– Chris Adams, Ph.D., Chief Business Officer,
– James McArthur, Ph.D., Chief Scientific Officer, and
– and Deborah Geraghty, Ph.D., Vice President, Project and Portfolio Development.
FinSMEs
11/04/2013